Prelude(FRANCE) | $8,000,000 | (Nov 14, 2024)
Camouflet | $3,000,000 | (Nov 14, 2024)
CHAOS Industries | $145,000,000 | (Nov 14, 2024)
Cell Microsystems
United States
- Durham, NC
- 21/11/2021
- Unknown
- $10,000,000
Cell Microsystems develops, manufactures, and markets innovative products for single cell biology. The Company’s proprietary CellRaft Technology enables high-efficiency sorting and isolation of single cells under standard culture conditions resulting in unperturbed phenotypes and high viability. Coupled with the Company’s automated imaging platform, a user can select a cell in real-time and ‘track and trace’ that cell through imaging, collection and downstream analysis. By sorting during real-time imaging, no cells are wasted enabling single cell isolation from even small, precious Cell Microsystems develops, manufactures, and markets innovative products for single cell biology. The Company’s proprietary CellRaft® Technology enables high-efficiency clonal propagation from single cells under standard culture conditions resulting in unperturbed phenotypes and high viability. Coupled with the Company’s AIR System automated imaging platform, a user can identify a cell in real-time and ‘track and trace’ that cell through cell division and imaging, propagation, and collection for downstream analysis. The CellRaft Technology offers scalable solutions making cell separation technology available for every lab. samples. The CellRaft Technology offers scalable solutions making cell separation technology available for every lab.
- Industry Biotechnology Research
- Website https://cellmicrosystems.com/
- LinkedIn https://www.linkedin.com/company/cellmicrosystems/
Related People
Gary PaceFounder
United States -
Raleigh-Durham-Chapel Hill Area
Over thirty years of experience in the life science field, with 20 years legal and corporate experience and 12 years in biotech research for large and small companies. He is a registered patent attorney with a record of over 40 issued US patents. Since 2001 he has helped many early and development stage companies in the life sciences with their strategic, intellectual property, and transactional activities in the areas of recombinant technology, drug discovery, drug development, therapeutic proteins, medical devices, advanced biomaterials, microfluidics, pharmacogenomics, and molecular diagnostics. Dr. Pace has held executive management positions in several companies, including Novartis Corporation, Gentris Corporation, Quill Medical, Inc., and BASF Corporation. Dr. Pace has a J.D. degree from the School of Law at North Carolina Central University, and his Ph.D. from North Carolina State University. He has been CEO at Cell Microsystems since 2014.
Arbolus | $20,000,000 | (Nov 14, 2024)
Trolley | $23,000,000 | (Nov 14, 2024)
Notabene | $14,500,000 | (Nov 14, 2024)
Pikndel | $1,000,000 | (Nov 14, 2024)
Zeplyn | $3,000,000 | (Nov 14, 2024)
High Basin Brands | $4,000,000 | (Nov 14, 2024)
Accelsius | $24,000,000 | (Nov 14, 2024)
Metsera | $215,000,000 | (Nov 14, 2024)
InVintory | $2,300,000 | (Nov 14, 2024)